rethinkTHC Search
Menu
Study breakdown

Clinical trial tested how CBD changes THC effects when taken together orally

Randomized Controlled TrialHigh evidence
The takeaway

A randomized clinical trial in healthy adults found that co-administered CBD altered THC pharmacokinetics and pharmacodynamics in a dose-dependent manner, providing controlled data on how the two cannabinoids interact when taken orally.

Clinical pharmacologists, medical cannabis prescribers, product formulators, and researchers studying cannabinoid interactions.

CBD dose-dependently modified THC pharmacokinetics and pharmacodynamics

What the researchers found

CBD co-administration modified THC blood levels and subjective effects in a dose-dependent pattern. The pharmacokinetic and pharmacodynamic interactions between oral THC and CBD varied depending on the ratio of the two cannabinoids.

Why it matters

CBD is widely believed to counteract THC effects, but controlled clinical data has been limited. This trial provides rigorous pharmacological evidence on how the two most prominent cannabinoids interact in humans.

The numbers in context

Multiple oral cannabis extract formulations with varying THC:CBD ratios tested. Blood THC levels and subjective effects measured. Dose-dependent CBD modulation of THC observed.

How the study worked

Randomized clinical trial in healthy adults. Compared pharmacokinetics and pharmacodynamics of orally administered cannabis extracts varying in THC and CBD concentrations. Measured blood levels and subjective effects.

What this study cannot tell us

Healthy adult volunteers may not reflect patients with medical conditions. Oral administration only (inhaled routes may produce different interactions). Acute dosing study does not capture chronic use dynamics. Specific extract formulations may not represent all commercial products.

How to read the evidence

Randomized clinical trial with pharmacokinetic and pharmacodynamic endpoints. Rigorous design for a drug interaction study.

When this study was published

Published 2023.

The bigger picture

The THC-CBD interaction is central to cannabis product design and medical cannabis prescribing. Rigorous pharmacokinetic data helps move from anecdotal "entourage effect" claims to evidence-based formulation decisions.

Questions still open

  • Does the THC-CBD interaction differ with chronic use? Would different delivery routes (inhaled, sublingual) show the same pharmacokinetic patterns?

Common questions

Does CBD reduce the effects of THC?
This clinical trial found the interaction is more nuanced than a simple reduction. CBD altered THC blood levels and subjective effects in a dose-dependent manner, meaning the ratio between the two matters. Some effects were attenuated while the pharmacokinetic picture was complex.
Why does the THC:CBD ratio matter?
Different ratios of THC to CBD produced different blood level profiles and subjective effects in this trial. This means that cannabis products with the same total cannabinoid content but different ratios could produce meaningfully different experiences and therapeutic effects.

Read the original research

Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.

JAMA network open, 6(2), e2254752

Citation

Zamarripa, C Austin; Spindle, Tory R; Surujunarain, Renuka; Weerts, Elise M; Bansal, Sumit; Unadkat, Jashvant D; Paine, Mary F; Vandrey, Ryan. (2023). Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.. JAMA network open, 6(2), e2254752. https://doi.org/10.1001/jamanetworkopen.2022.54752

Explore the wider topic